Investor Presentaiton
Novo Nordisk Annual Report 2023
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information
6
Novo Nordisk
at a glance
Novo Nordisk is a leading global healthcare company,
founded in 1923 and headquartered in Denmark.
Our purpose and strategy
Our business is built around the Novo Nordisk Way, our commitment to be a sustainable
business and our clear patient-centric purpose: driving change to defeat serious chronic
diseases. Our key contribution is to discover and develop innovative medicines and make
them accessible to patients throughout the world. We will strengthen our leadership in
diabetes and obesity, secure a leading position within rare disease and establish
ourselves in cardiovascular disease (CVD). We also aim to build a presence in emerging
therapy areas, such as metabolic dysfunction-associated steatohepatitis (MASH), chronic
kidney disease (CKD) and Alzheimer's disease (AD), and to move toward disease-modifying
and curative therapies.
41.6
million people living with
diabetes and obesity reached
232,261
DKK million
in net sales
102,574
DKK million
in operating profit
68,326
DKK million
in free cash flow
Diabetes
Strengthen leadership
by offering innovative
medicines and driving
patient outcomes
Novo
Nordisk
Way
Driving change
to defeat serious
chronic diseases
64,319
employees
worldwide
80
countries with
affiliates
5
countries with
R&D facilities
Rare Disease
Secure a leading position
by leveraging full portfolio and
expanding into adjacent areas
Sustainable
Obesity
Strengthen leadership through
market development and by
offering innovative medicines and
driving patient outcomes
business
Cardiovascular &
Emerging Therapy
Areas¹
Establish position in
cardiovascular disease and
build a presence in emerging
therapy areas
1. Other Serious Chronic Disease (OSCD) has been renamed to Cardiovascular & Emerging Therapy Areas (CETA) to reflect that cardiovascular disease has
been the main strategic priority within OSCD.View entire presentation